Drugs
MONOBEST drug
Our research and development activities, carried out in collaboration with the University of Insubria, enabled us to obtain the European patent “Peripheral blood mononucleate cells formulations subjected to hypoxia.”
Based on these studies, we formulated MONOBEST, an ATMP drug designed to support revascularization processes. Currently, preclinical tests are underway to evaluate its efficacy and safety.
The active ingredient
The active ingredient of MONOBEST is given by the presence of mononuclear cells isolated from cord blood and subjected to hypoxia. Such treatment increases the angiogenic capacity of the cell population.
Therapeutic benefits
MONOBEST represents an innovative alternative to conventional therapies, particularly for patients who cannot undergo arterial reconstruction or endovascular therapy. The drug has high angiogenic and vasculogenic capacity, offering a new therapeutic avenue for the treatment of peripheral arterial and venous disease.
Competitive advantages
MONOBEST offers more advanced technology than the leading therapeutic treatments available on the market. Its technology, based on hypoxically pretreated umbilical cord mononuclear cells, is an innovative solution that stands out in the field of regenerative medicine.
What others say
about us
Protsmart™
L'utilizzo di Protsmart™ nei nostri protocolli ha notevolmente migliorato i risultati delle terapie PRP, con pazienti che riferiscono minor dolore e più rapida guarigione.
IDRIA S+
Dopo il trattamento con IDRIA S+, ho notato un miglioramento sostanziale nell'infiammazione e nel dolore al ginocchio.
